Payer-Pharma Collaboration Through Value-Based Contracts is Set to AccelerateNews
Scientific advancements have created miracle cures for seemingly intractable diseases—along with astronomic price tags. Now, a new trend is exciting pharma, payers, physicians, patients and even analysts: linking drug reimbursement to patient outcomes. As this payment structure expands beyond chronic disease into specialty disease, how do you decide what a drug is worth?
In this article, Precision for Value’s chief medical officer Dominic Galante, parses the options.
Click here to read the full article.